ILUMYA (tildrakizumab-asmm) approved in the U.S. for the treatment of adults with active Psoriatic Arthritis
The filing
ILUMYA (tildrakizumab-asmm) approved in the U.S. for the treatment of adults with active Psoriatic Arthritis
- Company
- Sun Pharmaceutical Industries Ltd · BSE 524715
- Filed
- 30 October 2026, 08:05 IST
- BSE category
- Company Update / Press Release / Media Release
- Tag
- Press Release · selected
- Source
- Open the filing on BSE →
Why it led
- Large cap · NIFTY 50
Selected by the ranker from 4 filings that day. Each line above is a component of that score, not a comment on the filing.
How often this tag appears
2,025 of 82,708 filings in the published window carry Press Release · 2.45%
Around it
Most recent filings from Sun Pharmaceutical Industries Ltd
- Allotment Allotment
- Press Release / Media Release Press Release
- Press Release / Media Release Press Release
The company
Sun Pharmaceutical Industries Ltd
BSE 524715 · NSE SUNPHARMA · ISIN INE044A01036 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Full figures, price and filing history for Sun Pharmaceutical Industries Ltd →